Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Respiratory Aspiration 1Lymphoma, Follicular 1COVID-19 1

Interventions

Standard of Care 8Surveys and Questionnaires 7COVID-19 Vaccines 6Blood Specimen Collection 6BNT162 Vaccine 6Specimen Handling 52019-nCoV Vaccine mRNA-1273 5Hydroxychloroquine 4Surgical Procedures, Operative 3Practice Guidelines as Topic 3tocilizumab 2sotrovimab 2sinovac COVID-19 vaccine 2cilgavimab and tixagevimab drug combination 2Sodium Chloride 2Pandemic Preparedness 2Data Collection 2CVnCoV COVID-19 vaccine 2COH04S1 COVID-19 vaccine 2Azithromycin 2selinexor 1remdesivir 1regorafenib 1proxalutamide 1palbociclib 1ogalvibart 1monalizumab 1lenzilumab 1heterologous prime boost COVID-19 vaccination 1crexavibart 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
COVID-19 × IBIO123 × Clear all
NCT05303376 2023-09-13

Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness

Immune Biosolutions Inc

Phase 1/2 Completed
123 enrolled
Lymphoid

COVID-19, Lymphoma, Follicular, Respiratory Aspiration

Data powered by HemOnc (CC BY 4.0) Colophon âš¡